Analysts Set Definitive Healthcare Corp. (NASDAQ:DH) Target Price at $9.94

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have earned an average rating of “Hold” from the eleven ratings firms that are covering the stock, Marketbeat reports. Nine analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $9.94.

A number of brokerages have commented on DH. Stifel Nicolaus decreased their price target on shares of Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating for the company in a research note on Wednesday, May 8th. William Blair reaffirmed an “outperform” rating on shares of Definitive Healthcare in a report on Tuesday, May 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a report on Wednesday, May 8th. Barclays cut their price objective on shares of Definitive Healthcare from $11.00 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, May 9th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on shares of Definitive Healthcare from $10.00 to $7.00 and set a “hold” rating on the stock in a report on Thursday, May 9th.

Definitive Healthcare Stock Performance

Shares of DH stock opened at $5.44 on Friday. The firm has a market capitalization of $641.54 million, a PE ratio of -3.11, a price-to-earnings-growth ratio of 3.93 and a beta of 1.30. The firm has a fifty day simple moving average of $5.54 and a two-hundred day simple moving average of $7.47. The company has a current ratio of 2.30, a quick ratio of 2.30 and a debt-to-equity ratio of 0.20. Definitive Healthcare has a 12 month low of $4.38 and a 12 month high of $12.45.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). The business had revenue of $63.48 million for the quarter, compared to the consensus estimate of $64.00 million. Definitive Healthcare had a negative net margin of 78.16% and a positive return on equity of 0.51%. Analysts forecast that Definitive Healthcare will post 0.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its position in Definitive Healthcare by 599.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,786 shares of the company’s stock worth $58,000 after purchasing an additional 4,959 shares during the period. Norden Group LLC bought a new position in Definitive Healthcare during the first quarter worth about $83,000. Berry Wealth Group LP bought a new position in Definitive Healthcare during the first quarter worth about $99,000. Reynders McVeigh Capital Management LLC bought a new position in Definitive Healthcare during the fourth quarter worth about $129,000. Finally, Arizona State Retirement System boosted its position in Definitive Healthcare by 13.6% during the fourth quarter. Arizona State Retirement System now owns 14,253 shares of the company’s stock worth $142,000 after purchasing an additional 1,701 shares during the period. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.